Nektar Therapeutics (NASDAQ:NKTR) has been given a consensus recommendation of “Buy” by the sixteen analysts that are currently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. The average 1-year target price among analysts that have covered the stock in the last year is $48.18.
A number of analysts have recently commented on the company. BidaskClub cut Nektar Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 8th. Mizuho reissued a “buy” rating and issued a $89.00 price target on shares of Nektar Therapeutics in a research report on Wednesday, February 14th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 16th. Jefferies Group boosted their price target on Nektar Therapeutics from $2.12 to $88.00 and gave the stock a “buy” rating in a research report on Tuesday, January 16th. Finally, Canaccord Genuity reissued a “buy” rating and issued a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th.
Shares of Nektar Therapeutics (NKTR) opened at $83.45 on Wednesday. The company has a debt-to-equity ratio of 2.91, a current ratio of 4.14 and a quick ratio of 3.99. Nektar Therapeutics has a 12-month low of $12.50 and a 12-month high of $99.02. The company has a market capitalization of $13,381.02, a P/E ratio of -115.90 and a beta of 2.04.
In related news, SVP Stephen K. Doberstein sold 2,426 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $82.94, for a total value of $201,212.44. Following the transaction, the senior vice president now directly owns 67,394 shares of the company’s stock, valued at approximately $5,589,658.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Howard W. Robin sold 83,333 shares of the company’s stock in a transaction that occurred on Wednesday, December 13th. The shares were sold at an average price of $55.69, for a total value of $4,640,814.77. Following the completion of the transaction, the chief executive officer now directly owns 272,768 shares in the company, valued at $15,190,449.92. The disclosure for this sale can be found here. Insiders sold a total of 222,781 shares of company stock worth $14,884,901 over the last ninety days. 5.44% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. BB&T Investment Services Inc. bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $119,000. Meeder Asset Management Inc. bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $121,000. Oppenheimer Asset Management Inc. bought a new position in Nektar Therapeutics in the 3rd quarter valued at approximately $129,000. Mark Sheptoff Financial Planning LLC lifted its position in Nektar Therapeutics by 79.4% in the 3rd quarter. Mark Sheptoff Financial Planning LLC now owns 6,100 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 2,700 shares in the last quarter. Finally, SeaCrest Wealth Management LLC bought a new position in Nektar Therapeutics in the 4th quarter valued at approximately $200,000. 96.23% of the stock is currently owned by institutional investors and hedge funds.
About Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.